Arrowhead Pharmaceuticals IncNASDAQ:ARWR
- LAST PRICE18.2800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots18.0000/ 10
- Ask / Lots19.8500/ 1
- Open / Previous Close--- / 18.2800
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ARWR |
|---|---|---|
| 09:32 ET | 9211 | 18.5301 |
| 09:33 ET | 500 | 18.61 |
| 09:35 ET | 419 | 18.615 |
| 09:37 ET | 500 | 18.5 |
| 09:39 ET | 820 | 18.505 |
| 09:42 ET | 900 | 18.5 |
| 09:44 ET | 800 | 18.55 |
| 09:46 ET | 2600 | 18.545 |
| 09:48 ET | 2375 | 18.49 |
| 09:50 ET | 1408 | 18.57 |
| 09:51 ET | 3099 | 18.56 |
| 09:53 ET | 821 | 18.544984 |
| 09:55 ET | 809 | 18.605 |
| 09:57 ET | 1200 | 18.52 |
| 10:00 ET | 1216 | 18.45 |
| 10:02 ET | 1452 | 18.425 |
| 10:04 ET | 6083 | 18.26 |
| 10:06 ET | 100 | 18.285 |
| 10:08 ET | 1200 | 18.285 |
| 10:09 ET | 2410 | 18.32 |
| 10:11 ET | 1157 | 18.36 |
| 10:13 ET | 1053 | 18.34101 |
| 10:15 ET | 4216 | 18.38 |
| 10:18 ET | 1805 | 18.425 |
| 10:20 ET | 615 | 18.46 |
| 10:22 ET | 669 | 18.48 |
| 10:24 ET | 1100 | 18.47 |
| 10:26 ET | 365 | 18.42 |
| 10:27 ET | 723 | 18.44 |
| 10:29 ET | 300 | 18.38 |
| 10:31 ET | 1295 | 18.38 |
| 10:33 ET | 1405 | 18.42 |
| 10:36 ET | 924 | 18.41 |
| 10:38 ET | 1476 | 18.43 |
| 10:40 ET | 500 | 18.43 |
| 10:42 ET | 1000 | 18.37 |
| 10:44 ET | 1892 | 18.43 |
| 10:45 ET | 1143 | 18.41 |
| 10:47 ET | 1700 | 18.37 |
| 10:49 ET | 716 | 18.36 |
| 10:51 ET | 1300 | 18.41 |
| 10:54 ET | 200 | 18.43 |
| 10:56 ET | 3233 | 18.41 |
| 10:58 ET | 503 | 18.43 |
| 11:00 ET | 200 | 18.435 |
| 11:02 ET | 400 | 18.4625 |
| 11:03 ET | 2047 | 18.39 |
| 11:05 ET | 1843 | 18.35 |
| 11:07 ET | 1100 | 18.34 |
| 11:09 ET | 1300 | 18.31 |
| 11:12 ET | 700 | 18.3 |
| 11:14 ET | 400 | 18.305 |
| 11:16 ET | 3320 | 18.31 |
| 11:18 ET | 1386 | 18.31 |
| 11:20 ET | 2813 | 18.35 |
| 11:21 ET | 2470 | 18.33 |
| 11:23 ET | 5825 | 18.345 |
| 11:25 ET | 2348 | 18.39 |
| 11:27 ET | 600 | 18.37 |
| 11:30 ET | 600 | 18.36 |
| 11:32 ET | 300 | 18.35 |
| 11:34 ET | 704 | 18.36 |
| 11:36 ET | 1719 | 18.4 |
| 11:38 ET | 3800 | 18.4 |
| 11:39 ET | 1500 | 18.47 |
| 11:41 ET | 400 | 18.41 |
| 11:43 ET | 700 | 18.43 |
| 11:45 ET | 200 | 18.44 |
| 11:48 ET | 700 | 18.4 |
| 11:50 ET | 600 | 18.4274 |
| 11:52 ET | 2663 | 18.47 |
| 11:54 ET | 400 | 18.475 |
| 11:56 ET | 1000 | 18.48 |
| 11:57 ET | 1300 | 18.5 |
| 11:59 ET | 2078 | 18.51 |
| 12:01 ET | 2835 | 18.515 |
| 12:03 ET | 683 | 18.54 |
| 12:06 ET | 900 | 18.52 |
| 12:08 ET | 909 | 18.495 |
| 12:10 ET | 3122 | 18.51 |
| 12:12 ET | 4600 | 18.515 |
| 12:14 ET | 1200 | 18.545 |
| 12:15 ET | 1862 | 18.535 |
| 12:17 ET | 2679 | 18.555 |
| 12:19 ET | 708 | 18.58 |
| 12:21 ET | 1400 | 18.605 |
| 12:24 ET | 600 | 18.59 |
| 12:26 ET | 500 | 18.57 |
| 12:28 ET | 1940 | 18.56 |
| 12:30 ET | 829 | 18.605 |
| 12:32 ET | 2846 | 18.635 |
| 12:33 ET | 1220 | 18.64 |
| 12:35 ET | 1828 | 18.62 |
| 12:37 ET | 800 | 18.67 |
| 12:39 ET | 421 | 18.67 |
| 12:42 ET | 400 | 18.69 |
| 12:44 ET | 500 | 18.7 |
| 12:46 ET | 1136 | 18.735 |
| 12:48 ET | 5316 | 18.74 |
| 12:50 ET | 200 | 18.75 |
| 12:51 ET | 700 | 18.73 |
| 12:53 ET | 470 | 18.77 |
| 12:55 ET | 400 | 18.77 |
| 12:57 ET | 1854 | 18.8 |
| 01:00 ET | 400 | 18.79 |
| 01:02 ET | 100 | 18.79 |
| 01:04 ET | 440 | 18.82 |
| 01:06 ET | 551 | 18.795 |
| 01:08 ET | 1500 | 18.755 |
| 01:09 ET | 1672 | 18.78 |
| 01:13 ET | 1011 | 18.78 |
| 01:15 ET | 400 | 18.79 |
| 01:18 ET | 900 | 18.745 |
| 01:20 ET | 1079 | 18.76 |
| 01:22 ET | 800 | 18.77 |
| 01:24 ET | 954 | 18.8 |
| 01:26 ET | 2450 | 18.785 |
| 01:29 ET | 700 | 18.79 |
| 01:31 ET | 14333 | 18.795 |
| 01:33 ET | 611 | 18.8059 |
| 01:36 ET | 300 | 18.805 |
| 01:38 ET | 638 | 18.825 |
| 01:40 ET | 1800 | 18.785 |
| 01:42 ET | 1700 | 18.7 |
| 01:44 ET | 224 | 18.72 |
| 01:45 ET | 344 | 18.73 |
| 01:47 ET | 1800 | 18.66 |
| 01:49 ET | 1443 | 18.67 |
| 01:51 ET | 500 | 18.64 |
| 01:54 ET | 1068 | 18.62 |
| 01:56 ET | 997 | 18.65 |
| 01:58 ET | 11778 | 18.61 |
| 02:00 ET | 1125 | 18.65 |
| 02:02 ET | 400 | 18.64 |
| 02:03 ET | 100 | 18.635 |
| 02:05 ET | 500 | 18.63 |
| 02:09 ET | 1529 | 18.62 |
| 02:12 ET | 800 | 18.62 |
| 02:14 ET | 1239 | 18.64 |
| 02:16 ET | 701 | 18.63 |
| 02:18 ET | 1229 | 18.635 |
| 02:20 ET | 300 | 18.635 |
| 02:21 ET | 400 | 18.615 |
| 02:23 ET | 470 | 18.64 |
| 02:25 ET | 1696 | 18.7 |
| 02:27 ET | 1300 | 18.67 |
| 02:30 ET | 1754 | 18.635 |
| 02:34 ET | 1519 | 18.63 |
| 02:36 ET | 350 | 18.62 |
| 02:38 ET | 300 | 18.61 |
| 02:39 ET | 967 | 18.62 |
| 02:41 ET | 1000 | 18.59 |
| 02:43 ET | 400 | 18.58 |
| 02:45 ET | 1726 | 18.5726 |
| 02:48 ET | 100 | 18.59 |
| 02:50 ET | 1000 | 18.54 |
| 02:52 ET | 2229 | 18.55 |
| 02:54 ET | 2622 | 18.55 |
| 02:56 ET | 437 | 18.54 |
| 02:57 ET | 1921 | 18.53 |
| 02:59 ET | 7778 | 18.49 |
| 03:01 ET | 1862 | 18.5 |
| 03:03 ET | 502 | 18.485 |
| 03:06 ET | 298 | 18.49 |
| 03:08 ET | 2305 | 18.535 |
| 03:10 ET | 1295 | 18.56 |
| 03:12 ET | 1140 | 18.55 |
| 03:14 ET | 971 | 18.56 |
| 03:15 ET | 1500 | 18.57 |
| 03:17 ET | 4897 | 18.5651 |
| 03:19 ET | 3002 | 18.6 |
| 03:21 ET | 450 | 18.595 |
| 03:24 ET | 500 | 18.562 |
| 03:26 ET | 2758 | 18.53 |
| 03:28 ET | 427 | 18.51 |
| 03:30 ET | 3245 | 18.541 |
| 03:32 ET | 2966 | 18.515 |
| 03:33 ET | 4494 | 18.5 |
| 03:35 ET | 3332 | 18.462 |
| 03:37 ET | 1636 | 18.435 |
| 03:39 ET | 2700 | 18.385 |
| 03:42 ET | 9487 | 18.39 |
| 03:44 ET | 4603 | 18.37 |
| 03:46 ET | 4769 | 18.39 |
| 03:48 ET | 5565 | 18.36 |
| 03:50 ET | 4669 | 18.31 |
| 03:51 ET | 9994 | 18.31 |
| 03:53 ET | 11735 | 18.32 |
| 03:55 ET | 9327 | 18.34 |
| 03:57 ET | 22485 | 18.3 |
| 04:00 ET | 178744 | 18.28 |
Nov 20, 2024
DJ Arrowhead Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co., from 1:17PM ET on Wednesday Nov 20, 2024 by Dow Jones
1:17PM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 18, 2024
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome, from 7:31AM ET on Monday Nov 18, 2024 by Dow Jones
7:31AM ET on Monday Nov 18, 2024 by Dow JonesArrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran, from 7:30AM ET on Monday Nov 18, 2024 by Dow Jones
7:30AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 5, 2024
Press Release: Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results, from 7:31AM ET on Tuesday Nov 05, 2024 by Dow Jones
7:31AM ET on Tuesday Nov 05, 2024 by Dow JonesArrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results, from 7:30AM ET on Tuesday Nov 05, 2024 by Dow Jones
7:30AM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Arrowhead Pharmaceuticals Inc | 2.3B | -3.9x | --- |
Mirum Pharmaceuticals Inc | 2.1B | -20.5x | --- |
MannKind Corp | 1.9B | 97.0x | --- |
Twist Bioscience Corp | 2.5B | -11.6x | --- |
Dynavax Technologies Corp | 1.6B | 101.3x | --- |
Zai Lab Ltd | 2.9B | -9.2x | --- |
Company Information
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.
Contact Information
- Headquarters
- 177 E Colorado Blvd, Suite 700PASADENA, CA, United States 91105
- Phone
- 626-696-4702
- Fax
- 626-304-3401
Executives
- Independent Chairman of the Board
- Douglass Given
- President, Chief Executive Officer, Director
- Christopher Anzalone
- Chief Financial Officer
- Kenneth Myszkowski
- Chief Operating Officer, General Counsel, Company Secretary
- Patrick O'Brien
- Chief of Discovery and Translational Medicine
- James Hamilton
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.3B |
|---|---|
Revenue (TTM) | $19.6M |
Shares Outstanding | 124.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.81 |
EPS | $-4.65 |
Book Value | $2.53 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | 115.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,785.05% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
